A combination of platelet features allows detection of early-stage cancer by Sabrkhany, Siamack et al.
 
 
 
A combination of platelet features allows detection of
early-stage cancer
Citation for published version (APA):
Sabrkhany, S., Kuijpers, M. J. E., van Kuijk, S. M. J., Sanders, L., Pineda, S., Damink, S. W. M. O.,
Dingemans, A-M. C., Griffioen, A. W., & Egbrink, M. G. A. O. (2017). A combination of platelet features
allows detection of early-stage cancer. European Journal of Cancer, 80, 5-13.
https://doi.org/10.1016/j.ejca.2017.04.010
Document status and date:
Published: 01/07/2017
DOI:
10.1016/j.ejca.2017.04.010
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 08 Jan. 2021
European Journal of Cancer 80 (2017) 5e13Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.ejcancer .comOriginal ResearchA combination of platelet features allows detection of
early-stage cancerSiamack Sabrkhany a, Marijke J.E. Kuijpers b, Sander M.J. van Kuijk c,
Linda Sanders a, Sharo Pineda a, Steven W.M. Olde Damink d,
Anne-Marie C. Dingemans e, Arjan W. Griffioen f,
Mirjam G.A. oude Egbrink a,*a Department of Physiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centerþ,
Maastricht, The Netherlands
b Department of Biochemistry, Maastricht University Medical Centerþ, Maastricht, The Netherlands
c Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centerþ,
Maastricht, The Netherlands
d Department of Surgery, Maastricht University Medical Centerþ, Maastricht, The Netherlands
e Department of Pulmonology, Maastricht University Medical Centerþ, Maastricht, The Netherlands
f Department of Medical Oncology, Angiogenesis Laboratory, VU Medical Center, Amsterdam, The NetherlandsReceived 21 February 2017; received in revised form 2 April 2017; accepted 5 April 2017
Available online 17 May 2017KEYWORDS
Platelets;
Biomarker;
Cancer* Corresponding author: Department o
3884166.
E-mail address: m.oudeegbrink@ma
http://dx.doi.org/10.1016/j.ejca.2017.04.0
0959-8049/ª 2017 Elsevier Ltd. All righAbstract Background: Detection of early-stage cancer significantly improves patient sur-
vival. As platelets play an important role in cancer progression, we aimed to investigate
whether platelets can be used for the discovery of early-stage cancer.
Methods: Patients with lung (n Z 86) or head of pancreas (n Z 42) cancer were included, as
were healthy sex- and age-matched controls (n Z 92). Blood was collected before initiation of
treatment. Platelet count, volume and activation status were quantified in whole blood. Next,
concentrations of vascular endothelial growth factor, platelet-derived growth factor, platelet
factor 4, thrombospondin-1 and connective tissueeactivating peptide III were measured in
both platelets and plasma. Using the results, two multivariable diagnostic models were devel-
oped and internally validated.
Findings: Multiple platelet features, including platelet count, volume and protein content,
were significantly changed in lung and head of pancreas cancer patients. However, the patternf Physiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Fax: þ31 43
astrichtuniversity.nl (M.G.A. oude Egbrink).
10
ts reserved.
S. Sabrkhany et al. / European Journal of Cancer 80 (2017) 5e136of changes differed between both groups. The diagnostic model developed for lung cancer
discriminated very well between patients and controls (AUC Z 88.7%). Addition of smoking
as a variable significantly increased the AUC of the model to 94.5%. The diagnostic model for
head of pancreas cancer also performed well (AUC Z 82.7%). Both models were internally
validated, resulting in optimism-corrected AUC’s of 86.8% and 80.8%, respectively.
Interpretation: In patients with lung or head of pancreas cancer, several platelet characteristics
are changed compared to healthy sex- and age-matched controls. A cancer type-specific com-
bination of these platelet features can be used to discriminate between patients with early-stage
cancer and healthy individuals.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
Detection of cancer in its early stages radically improves
the effectiveness of available treatment and overall
prognosis of patients [1]. Up to now, studies searching
for biomarkers are mostly based on blood plasma or
serum parameters. A limitation of this approach is that
platelets and their content are neglected [2].
Circulating platelets contain numerous proteins,
including growth factors, chemokines and proteases,
which are synthesised by megakaryocytes or absorbed
from the blood by the platelets themselves [3]. There-
fore, the presence of a growth factor-producing tumour
can influence platelet content. Concentrations of
angiogenic factors, like vascular endothelial growth
factor (VEGF) and platelet-derived growth factor
(PDGF), and the angiostatic platelet factor 4 (PF4) have
been reported to be higher in platelets of patients with
cancer than in platelets of healthy individuals [4,5].
Another recent study suggests that platelet mRNA
profiles are also altered in patients with cancer, enabling
discrimination between cancer patients and healthy in-
dividuals [6]. In addition, platelets may become acti-
vated systemically or within the tumour, potentially
resulting in release of platelet content into the circula-
tion [3]. Next to platelet content and platelet activation,
platelet count is also frequently changed in cancer pa-
tients [7]. Tumours can increase platelet production by
secretion of thrombopoietic cytokines, leading to para-
neoplastic thrombocytosis [7,8].
Altogether, data from literature suggest that several
platelet characteristics are affected in cancer patients.
These features, either alone or in combination, may be
useful tools in the detection of (early stages of) cancer. It
was the aim of the present study to investigate, in two
different groups of cancer patients, whether and how
platelet features are changed in the presence of a
tumour. In addition, we succeeded to combine these
features into two internally validated diagnostic models,
one for lung cancer and another one for head of
pancreas cancer, to discriminate between patients and
healthy individuals.2. Methods
2.1. Study design and participants
This study was performed in accordance with the
Declaration of Helsinki and approved by the medical
ethical committee of Maastricht University Medical
Centerþ. Informed consent was obtained from all par-
ticipants. Patients with clinically established and histo-
logically proven untreated primary lung (n Z 86) or
head of pancreas cancer (n Z 42, including pancreas
head cancer [n Z 28], distal cholangiocarcinoma [n Z 8]
and duodenumcarcinoma [n Z 6]), that were eligible for
surgical resection, were included between July 2012 and
October 2014. Exclusion criteria were previous history
of cancer, neo-adjuvant chemotherapy or radiotherapy,
use of platelet-influencing drugs such as aspirin, blood
or platelet transfusion during the previous 14 days,
active inflammatory disease, non-healing ulcers or
fractures. Staging was performed in accordance with the
tumour-node-metastasis (TNM) classification (version
7) of the Union for International Cancer Control [9]. A
sex- and age-matched healthy control population for
both cancer groups was included as well (Table 1).
2.2. Procedures
Blood from all patients and healthy individuals was
collected. In case of cancer patients, sampling occurred
within 1 week before initiation of treatment. To prevent
platelet activation during blood collection and sample
preparation, blood was collected as described before
[10].
The procedures for quantification of platelet count,
volume and activation status, as well as concentrations
of various growth factors and chemokines in platelets
and plasma, are described extensively in the Appendix.
In short, platelet count and volume were determined in
whole blood with a Beckman coulter counter, and
platelet activation was quantified in whole blood using
flow cytometry. The remaining blood was centrifuged
several times to obtain platelet-free plasma (PFP) and
Table 1
Patient demographics and clinical profiles.
Lung cancer Head of pancreas cancer
Patients (n Z 86) Controls (n Z 86) P-value Patients (n Z 42) Controls (n Z 42) P-value
Age
Years (SD) 65.8 (8.6) 64.9 (9.8) 0.52 67.6 (10.5) 67.7 (10.7) 0.96
Gender 0.641 1.001
Male 53 (61.6%) 50 (58.1%) 21 (50.0%) 21 (50.0%)
Female 33 (38.4%) 36 (41.9%) 21 (50.0%) 21 (50.0%)
Smoking <0.0011 0.681
Current 30 (34.9%) 13 (15.1%) 9 (21.4%) 6 (14.3%)
Former 48 (55.8%) 18 (20.9%) 10 (23.8%) 10 (23.8%)
Never 8 (9.3%) 55 (64.0%) 23 (54.8%) 26 (61.9%)
TNM stage
IeII 39 (45.3%) e 29 (69.0%) e
IIIeIV 47 (54.7%) e 13 (31.0%) e
Primary tumour location
Lung 86 e e e
Pancreas head e e 28 e
Duodenum e e 6 e
Distal biliary duct e e 8 e
Histology
Adenocarcinoma 43 e 38 e
Squamous cell carcinoma 21 e e e
Large-cell carcinoma 2 e e e
Small-cell carcinoma 15 e e e
Other 5 e 4 e
Patient baseline characteristics were compared to data from the healthy control groups using the t-test for continuous variables and 1Pearson’s chi-
square test for categorical variables. P-values less than 0.05 were considered statistically significant.
SDZ standard deviation; TNM, tumour-node-metastasis.
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trations of the angiogenic proteins VEGF and PDGF,
as well as the angiostatic factors PF4, thrombospondin-
1 (TSP-1) and connective tissue-activating peptide III
(CTAPIII) were measured using specific human DuoSet
ELISA assays (R&D Systems, Abingdon, United
Kingdom). ELISA measurements in all patient and
matching control samples were performed using the
same assay, simultaneously and in the same institution.
2.3. Statistics
Statistical analyses were performed using SPSS (version
22; SPSS Inc, Chicago, USA) and R (version 3.2.2, R
core development team). Data are presented as means
with standard errors of the mean unless otherwise
indicated. Patient data were compared to data from the
healthy control groups using the t-test for continuous
variables and Pearson’s chi-square test for categorical
variables. Spearman’s rank correlation was used to test
the association between variables. P-values less than
0.05 were considered statistically significant.
2.4. Development of diagnostic models
For both cancer groups, logistic regression was used to
estimate diagnostic models. All platelet parameters were
added, after which stepwise backward elimination was
used to arrive at a more parsimonious model. Thederivation of the diagnostic model for lung cancer was
repeated to also include smoking status (current, former
and never) to assess its performance when combined with
arguably the strongest known predictor for lung cancer.
Model performance was assessed by Nagelkerke’s R2
statistic and by quantifying discrimination. Nagel-
kerke’s R2 can be used to quantify the predictive
strength of a diagnostic model. Discrimination is the
model’s ability to distinguish between those that have
cancer and those who do not. Discrimination was
quantified by the area under the receiver operating
characteristic curve (AUC). In addition, boxplots were
constructed to visually assess how the diagnostic model
distinguishes cases from controls.
Since the number of predictors that was entered in the
models was higher than recommended using the 10
events-per-variable rule of thumb, the risk of overfitting
the diagnostic models was relatively high. Therefore, the
models were internally validated using standard boot-
strapping techniques [11]. In this step, 1000 bootstrap
samples of the original data were drawn, and similar
diagnostic models were estimated using these data. The
average difference in diagnostic model performance
between the bootstrap sample and the original sample
provided estimates of optimism in the performance
measures. These measures of optimism were subse-
quently subtracted from the performance measures we
computed, to reflect the likely performance of the
models in future patients.
S. Sabrkhany et al. / European Journal of Cancer 80 (2017) 5e1383. Results
Blood was collected from 86 lung cancer patients, 42
patients diagnosed with head of pancreas cancer and a
total of 92 healthy individuals. Importantly, the latter
group contained individuals that were matched with
respect to gender and age to both groups of cancer pa-
tients. All cancer patients were treatment naive at the
moment of blood sampling. Detailed characteristics of
the study populations are presented in Table 1. The lung
cancer group comprised significantly more (current and
former) smokers than the control group. In the healthy
individuals, both gender and age appeared to be related
to some of the platelet characteristics. Mean platelet
count appeared to be higher in females than males (235
versus 201  109/L; p < 0.01), while age showed to be
negatively correlated with platelet concentrations of
PDGF (Spearman’s r: e0.43; p < 0.0001), PF4 (r:
e0.31; p < 0.01) and CTAPIII (r: e0.21; p < 0.05).C I-II III-IV
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Fig. 1. Lung cancer is associated with changes in platelet count, mea
Platelet characteristics were measured in healthy controls (C, n Z 86) a
TNM-stage (IeII, n Z 39; IIIeIV, n Z 47). (AeB) Whole blood plat
Platelets and platelet-free plasma (PFP) were isolated from whole blo
were determined in platelets (CeG) and PFP (HeL). Data are pre
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connective tissueeactivating peptide III; TSP-1, thrombospondin-1; V3.1. Platelet characteristics in patients with untreated lung
cancer
Platelet counts were not different as compared to con-
trols in patients with early-stage (stage IeII) lung can-
cer, but significantly increased in case of advanced (stage
IIIeIV) lung cancer (Fig. 1A). Mean platelet volume
(MPV) was higher in early-stage (stage IeII) lung cancer
only (Fig. 1B).
Concentrations of VEGF, PDGF, CTAPIII, PF4 and
TSP-1 in platelets appeared to differ significantly be-
tween lung cancer patients and controls. VEGF con-
centration was significantly elevated in platelets of both
stage IeII and stage IIIeIV patients (Fig. 1C), while
platelet PDGF concentration was elevated in stage IeII
only (Fig. 1D). In contrast, concentrations of CTAPIII,
PF4 and TSP-1 were similar to control in early-stage
cancer but significantly reduced in platelets of patients
with advanced lung cancer (Fig. 1EeG).I-II III-IV
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S. Sabrkhany et al. / European Journal of Cancer 80 (2017) 5e13 9Strikingly, changes in platelet content did not
correspond with concentration changes of the same
proteins in PFP (Fig. 1HeL). VEGF concentration was
decreased and PDGF concentration increased in
advanced stage lung cancer (Fig. 1H and I). CTAPIII
and PF4 concentrations (Fig. 1J and K) were elevated
in plasma of both early- and advanced-stage lung can-
cer patients, while TSP-1 plasma concentration was not
changed in any of the lung cancer patient groups
(Fig. 1L). To exclude the possibility that the increased
PDGF, CTAPIII and PF4 plasma levels in patients
result from ex vivo platelet activation (by blood
collection and preparation), we determined P-selectin
expression and integrin aIIbb3 activation on unstimu-
lated platelets of patients and controls by flow cytom-
etry. No differences between patients and controls were
found (Supplemental Fig. 1A and B). Furthermore, the
platelets were similarly responsive to in vitro activation
(Supplemental Fig. 1C and D). This suggests that the
increase in PDGF, CTAPIII and PF4 plasma concen-
trations in patients with lung cancer is mainly due to
systemic or intratumoural platelet activation, leading to
secretion of their content.
3.2. A combination of platelet features discriminates lung
cancer patients from controls
Data from 172 individuals (86 patients with lung cancer
and 86 sex- and age-matched controls) were available for
multivariable modelling. All measured parameters were
entered into the model: platelet count, MPV and con-
centrations of VEGF, PDGF, PF4, CTAPIII and TSP-1
in platelets and PFP. The stepwise backward elimination
procedure yielded a diagnostic model consisting of aA B
Platelet parameters 
AUC 88·7%; 95% CI 84·1 – 93·2
Platelet parameters and smoking
AUC 94·5%; 95% CI 91·0 – 98·1
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Fig. 2. A combination of platelet features allows discrimination betwee
of a final set of six parameters (platelet count, MPV, PF4 and CTAP
trations in PFP). (A) Receiver operating characteristic (ROC) curves o
and after addition of smoking as a variable (hatched line). (B) Boxplot o
platelet parameters of lung cancer patients and controls. PF4, platelet f
thrombospondin-1; MPV, mean platelet volume; PFP, platelet-free plfinal set of six parameters (platelet count, MPV, PF4 and
CTAPIII concentrations in platelets, and CTAPIII and
TSP-1 concentrations in PFP). Nagelkerke’s R2 of the
diagnostic model was 0.572, indicating that the model
fits the data well. Fig. 2A shows the performance of the
model with an area under the curve (AUC) of 88.7%
(95% confidence interval [CI] 84.1e93.2). The optimism-
corrected AUC (i.e. the likely value of the AUC when
applied to future patients) was 86.8%. This demonstrates
that the model discriminated very well between lung
cancer cases and controls in our study population. This
was confirmed by the boxplots of predicted probability
by the diagnostic model (Fig. 2B). The distribution of
probabilities of lung cancer cases and controls were
almost separated; there was only little overlap between
controls on the one hand and stage IeII and IIIeIV lung
cancer patients on the other. Addition of smoking as a
variable significantly increased the predicted probability
of the diagnostic model (p < 0$001, AUC Z 94.5% [95%
CI 91.0e98.1]; Fig. 2A).
3.3. A platelet-based marker for the presence of head of
pancreas cancer
In patients diagnosed with head of pancreas cancer,
several platelet parameters were found to be substantially
different from the control group as well. Platelet count
was significantly elevated in stage IeII (Fig. 3A)
and MPV in stage IIIeIV cancer (Fig. 3B). VEGF con-
centration was significantly increased in platelets of pa-
tients with early- and late-stage head of pancreas
cancer (Fig. 3C), while no differences in platelet
PDGF, CTAPIII, PF4 and TSP-1 concentrations were
observed (Supplemental Fig. 2AeD). In PFP, PDGFPr
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(subdivided according to TNM-stage: IeII, n Z 29 and IIIeIV, n Z 13). (AeB) Whole blood platelet count and MPV were measured
after blood collection. Platelets and platelet-free plasma (PFP) were isolated from whole blood and concentrations of VEGF, PDGF,
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(Fig. 3D), while PF4, CTAPIII and TSP-1 concentrations
were increased in plasma of patients with early- and late-
stage head of pancreas cancer (Fig. 3EeG). Strikingly,
VEGF concentrations in PFP were not different between
patients with head of pancreas cancer and healthy in-
dividuals (Supplemental Fig. 2E).
The stepwise backward elimination procedure yiel-
ded a diagnostic model for head of pancreas cancer
consisting of three parameters (platelet count, MPV
and VEGF concentration in platelets). Nagelkerke’s R2
of this model was 0.418, which is indicative of good
model fit. The discriminative ability, as expressed by
the AUC (Fig. 4A), was 82.7% (95% CI 74.1e91.6).
The optimism-corrected estimate of discriminative
ability was 80.8%. This parsimonious model discrimi-
nated well between patients with head of pancreas
cancer and controls, as confirmed by the boxplots of
predicted probability by the diagnostic model (Fig. 4B).
Addition of smoking as a variable did not change the
predicted probability of this diagnostic model (data not
shown).4. Discussion
The presence of a tumour in the human body appears to
influence several platelet features. In this study, we iden-
tified changes in platelet count, volume and protein con-
tent in patients with lung or head of pancreas cancer as
compared to healthy individuals matched for sex and age.
In addition, circulating platelets appeared to be activated
and plasma protein content was found to be different in
cancer patients. Although a number of changes were
similar in both patient groups, the precise change pattern
appeared to be cancer type specific. Multivariable
modelling of platelet characteristics enabled discrimina-
tion between lung or head of pancreas cancer patients,
already at an early stage, and their healthy control groups.
Previous studies have already shown that tumours
can affect platelet content of patients with cancer in
different ways. This results from the fact that both
platelets [12] and megakaryocytes [13] are able to
actively sequester tumour-derived proteins from their
microenvironment by endocytosis. We show an increase
of VEGF in platelets of patients with lung and head of
A B
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S. Sabrkhany et al. / European Journal of Cancer 80 (2017) 5e13 11pancreas cancer. This is in agreement with other studies
demonstrating an increase of VEGF in platelets of pa-
tients with colon [4], liver [14,15] and lung [5] cancer.
While platelet VEGF content appears to increase in all
investigated cancer types, changes in other platelet
growth factors in chemokines seem to be more cancer
type dependent. For example, we found an elevated
PDGF concentration in platelets of patients with early-
stage lung cancer, as did Peterson et al. [4] in colorectal
cancer patients. This contrasts with our findings in head
of pancreas cancer patients and data from another study
with hepatocellular carcinoma patients, indicating no
changes in platelet PDGF concentration [14]. Further-
more, we found that PF4, CTAPIII and TSP-1 con-
centrations were reduced in platelets of patients with
stage IIIeIV lung cancer, but not in platelets of patients
with head of pancreas cancer. Hepatocellular carcinoma
was reported to have no effect on platelet PF4 concen-
tration [14], and non-metastatic colorectal cancer
appeared to be accompanied by an increase in platelet
PF4 [4]. Overall, the above data support the notion of
tumour type dependency of platelet changes, an effect
thatddirectly or indirectly via megakaryocytesdmay be
due to differences in cancer cell secretome [16].
The elevated PF4 and CTAPIII concentrations in
plasma reveal the presence of activated platelets in the
circulation of patients with lung or head of pancreas
cancer. Also other studies used these parameters to
demonstrate in vivo platelet activation in patients with
cancer [17,18]. We excluded the possibility that the
increased plasma concentrations were the result of ex vivo
platelet activation during collection and handling of
blood by measuring P-selectin expression and integrin
aIIbb3 activation on the surface of the platelets by wholeblood flow cytometry. The fact that no differences be-
tween patients and controls were found and that platelets
were still equally responsive to in vitro activation, con-
firms the notion that the elevated PF4 and CTAPIII
concentrations in plasma are caused by platelet activation
in the circulation of cancer patients. This can occur within
the tumour vasculature, as well as systemically [19]. The
leaky, irregular tumour vasculature creates a pro-
thrombotic microenvironment by expressing proteins
such as collagen and/or tissue factor, which are potent
platelet activators [3]. In addition, cancer cells can secrete
or express platelet-activating factors such as thrombin,
adenosine diphosphate (ADP) and thromboxane A2 [20].
Similar to studies by others [7], we detected an
increased platelet count in patients with cancer. Malig-
nant cells produce thrombopoietic cytokines, leading to
paraneoplastic thrombocytosis [8]. Our finding that
MPV is elevated in peripheral blood of patients with
cancer is also in agreement with earlier findings [21].
There is evidence indicating that larger platelets are
metabolically and enzymatically more active than
smaller platelets, resulting in higher in vivo platelet
activation [22,23]. However, the exact underlying path-
ophysiological mechanism of the presence of larger
platelets in cancer patients is not fully understood.
Altogether, our study shows that multiple platelet
characteristics are changed in patients with cancer, both
in early and later stages of development. Therefore, a
multivariable diagnostic model was developed for both
cancer types. Performance of the model in the lung
cancer group, with six parameters (platelet count, MPV,
PF4 and CTAPIII concentrations in platelets, and
CTAPIII and TSP-1 concentrations in PFP), reached a
high AUC of 88.7% (95% CI 84.1e93.2). Addition of
S. Sabrkhany et al. / European Journal of Cancer 80 (2017) 5e1312the independent risk factor smoking as a variable
significantly increased the performance of the model,
achieving an AUC of 94.5% (95% CI 91.0e98.1). This
also corrects for potential effects of smoking on platelet
characteristics.
Exploiting the same strategy, another multivariable
diagnostic model was created for patients with head of
pancreas cancer, which included only three parameters
(platelet count, MPV and VEGF concentration in
platelets), but also performed well (AUC 82.7%; 95% CI
74.1e91.6). These findings strongly suggest that a
combination of platelet indices can be used to distin-
guish patients with cancer from healthy individuals.
Importantly, addition of a known risk factor such as
smoking in case of lung cancer improves the discrimi-
native power of such a model. The distribution of pre-
dicted probabilities of lung and head of pancreas cancer
patients showed only limited overlap with that of the
controls. This holds not only for stage IIIeIV patients
but also for stage IeII patients, suggesting discrimi-
nating power of a combination of platelet features for
early-stage cancer.
The diagnostic potential of platelets in cancer was
recently also highlighted by a study of Best et al. [6], who
demonstrated changes in platelet RNA profiles in pa-
tients with cancer, enabling discrimination between
cancer patients and healthy individuals with high
sensitivity and specificity. One important issue in this
interesting study is the nature of the control group, that
is clearly younger and with a different gender distribu-
tion than most of the cancer groups. Our data demon-
strate statistically significant effects of both sex and age
on various platelet characteristics, a finding that has
been reported before in other studies as well [24,25]. This
finding shows that inclusion of controls with similar sex
and age is a key feature in studies like this. Another
difference with our design is the fact that most patients
in the study of Best et al. [6] are in an advanced stage of
cancer, which leaves the question whether platelet RNA
profiles offer diagnostic opportunities for early-stage
cancer unanswered.
Overall, our study demonstrates that combinations of
platelet features are potential biomarkers of cancer, even
in patients with early-stage localised disease. The mini-
mally invasive way to obtain platelets offers an attrac-
tive alternative to detect and diagnose cancer, as
opposed to radiology and pathological analysis of tissue
biopsies with all associated limitations. Future research
is needed to further investigate the clinical relevance of
our findings. Larger patient groups and additional
cancer types have to be investigated. In addition, the
effect of cancer treatment on platelet characteristics
should be studied, to determine whether platelets could
be employed to monitor the response to treatment.
Platelets are a new and uncharted source of information,
which need to be further explored in blood-based
biomarker research.Funding
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